LONDON--(BUSINESS WIRE)--\u00a0<\/p>
\nXtrackers (IE) plc<\/b><\/p>
\nInvestment Company with Variable Capital<\/p>
\nRegistered Office: 78 Sir John Rogerson's Quay, Dublin 2, Ireland<\/p>
\nRegistration number: 393802<\/p>
\nCircular to the Shareholders and<\/b><\/p>
\nNotice of Extraordinary General Meeting of<\/b><\/p>
\nXtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (ISIN:<\/b> IE000KD0BZ68)<\/b><\/p>
\n(<\/b>the \u201cFund<\/b>\u201d)<\/b><\/p>
\n_________________________________________________________________________________<\/p>
\nThis document is important and requires the Shareholders\u00b4 immediate attention. Shareholders who are in doubt as to the action they should take should seek advice from their stockbroker, bank manager, solicitor, accountant or other independent financial advisor. The directors of Xtrackers (IE) plc (the Company) accept responsibility for the information contained in this document as being accurate as at the date of publication. Shareholders who have sold or transferred all of their shares in the Fund should pass this document to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected, for transmission to the purchaser or transferee as soon as possible.<\/b><\/p>
\nUnless otherwise defined or inconsistent with the context in this document, capitalised terms used herein have the same meanings as are ascribed to them in the current prospectus of the Company and supplement in respect of the Fund<\/b><\/p>
\n_________________________________________________________________________________<\/p>
\n03 August 2026<\/p>
\nNotice is hereby given that the directors of the Company (the \u201cDirectors<\/b>\u201d) have resolved to convene an Extraordinary General Meeting of the Shareholders of the Fund on 17 August 2026 at 10 a.m. (Dublin time) at 25 North Wall Quay, Dublin 1, D01 H104, Ireland (the \u201cMeeting<\/b>\u201d or the \u201cEGM<\/b>\u201d). Defined terms used which are not otherwise defined herein shall have the same meaning as in the Company\u2019s prospectus, as supplemented from time to time (the \u201cProspectus<\/b>\u201d) and the supplement in respect of the Fund (the \u201cSupplement<\/b>\u201d).<\/p>
\nThe Purpose of the Meeting<\/b><\/span><\/p> \nThe purpose of the Meeting is to enable Shareholders to consider a proposed change to the investment objective of the Fund and certain other changes as detailed below.<\/p> \nChange of Investment Objective<\/b><\/p> \nThe current investment objective of the Fund is to track the performance before fees and expenses of an index, which is the MSCI ACWI IMI Genomic Innovation Select Screened 100 Index (the \u201cCurrent Reference Index<\/b>\u201d).The Current Reference Index is based on the MSCI ACWI IMI Index (the \u201cCurrent Parent Index<\/b>\u201d), which includes large, medium, and small-capitalisation companies across developed and emerging markets globally. Constituents of the Current Parent Index which are assessed to have high exposure to business activities associated with the theme of technological innovation in the genomic healthcare sector (including, for example, genomic sequencing, synthesis, analysis or instrumentation, enabling bio computing, bioinformatics, molecular diagnostics, and agricultural biotechnology) and which meet certain environmental, social and governance (\u201cESG<\/b>\u201d) criteria are eligible for inclusion in the Current Reference Index. The Current Reference Index is administered by MSCI Limited (the \u201cIndex Administrator<\/b>\u201d).<\/p> \nIt is proposed that the investment objective of the Fund will be changed to track the performance before fees and expenses of an index which is designed to represent the performance of the shares of large and medium capitalisation companies in developed global markets that are classified within the Biotechnology Industry according to the Global Industry Classification Standard.<\/p> \nUpdated Investment Policy<\/b><\/p> \nIf the ordinary resolution is approved by the Shareholders of the Fund, the investment policy of the Fund will be changed to reflect that, in order to achieve its investment objective, the Fund will aim to replicate or track, before fees and expenses, the performance of the MSCI World Biotechnology 20\/35 Index (the \u201cNew Reference Index<\/b>\u201d).<\/p> \nFor the avoidance of doubt, the Fund will continue to adopt a Direct Investment Policy and be a Full Replication Fund.<\/p> \nOverview of the New Reference Index<\/b><\/p> \nThe New Reference Index is also administered by the Index Administrator.<\/p> \nThe New Reference Index is based on the MSCI World Index (the \u201cNew Parent Index<\/b>\u201d) includes large and medium capitalisation companies which aims to include 85% of the cumulative free float-adjusted market capitalisation in global developed markets.<\/p> \nAdditional relevant differences between the Current Reference Index and the New Reference Index include, but are not limited to the following:<\/p> \nESG<\/span>: The Current Reference Index applies certain ESG screens and criteria and the Fund currently promotes, among other characteristics, environmental and social characteristics and is subject to the disclosure requirements of a financial product under Article 8 of the Regulation (EU) 2019\/2088 of 27 November 2019 on sustainability-related disclosures in the financial services sector, as amended (\u201cSFDR<\/b>\u201d).<\/p> \nThe New Reference Index does not apply ESG screens and following the proposed changes, the Fund will not promote environmental or social characteristics and will not have sustainable investment or the reduction of carbon emissions as its objective. Therefore, the Fund will be subject to the disclosure requirements of a financial product under Article 6 of SFDR.<\/p>